Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement

Hemophagocytic Lymphohistiocytosis Clinical Trial

Official title:

Efficacy and Safety of Segmental Resection Combined With the DEP Regimen for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis With Intestinal Involvement

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06131489
• Other study ID #: BFH20230809002/BFHHZS20230190
• Status: Not yet recruiting
• Start date: December 1, 2023
• Est. completion date: January 1, 2027

Study information

• Verified date: September 2023
• Source: Beijing Friendship Hospital
• Contact: Zhao Wang, MD
• Phone: 63138303
• Email: wangzhao[@]ccmu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.

Description:

Epstein-Barr virus associated hemophagocytic lymphohistiocytosis is a rare disease with high mortality, especially for those with intestinal involvement. Some of them still died despite early control of the disease due to severe complications, such as gastrointestinal bleeding. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: January 1, 2027
• Est. primary completion date: December 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Met HLH-2004 diagnostic criteria;
• EBV-DNA in the peripheral blood > 1000 copies/ml or EBV-encoded small RNA (EBER) detected in tissues;
• Imaging revealed severe intestinal lesions and biopsy confirmed EBV-encoded small RNA (EBER) in the tissues;
• Age >18 years old, gender is not limited;
• Estimated survival time > 1 month;
• Informed consent obtained.

Exclusion Criteria:

• Active infections (viral, bacterial, fungal or parasitic);
• Diagosed with malignant tumos within 5 years;
• Uncontrolled symptoms or other diseases including, but not limited to, unstable angina pectoris, arrhythmia, respiratory failure, severe hepatic or renal insufficiency, severe coagulation dysfunction, mental illness, or other conditions deemed by the attending physician to be contraindications to surgery;
• Heart function above grade II (NYHA);
• Severe myocardial injury:TNT?TNI?CK-MB > 3 ULN;
• Accumulated dose of doxorubicin above 400mg/m2 ?epirubicin above 750mg/m2?pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease;
• Pregnancy or lactating Women;
• Allergic to pegylated liposomal doxorubicin and etoposide;
• HIV antibody positivity;
• Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable);
• Participate in other clinical research at the same time;
• The researchers considered that patients are not suitable for the study.

Related Conditions & MeSH terms

• Bowel Resection
• Epstein-Barr Virus Infections
• Hemophagocytic Lymphohistiocytosis
• Lymphohistiocytosis, Hemophagocytic

Intervention

Other:
• Segmental bowel resection combined with the DEP regimen
Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles

Locations

Country	Name	City	State
China	Zhao Wang	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Friendship Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR	The percentage of cases that achieved complete response (CR) and partial response (PR) after treatment.	4 Week
Primary	Adverse events	Incidence of adverse reactions	1 month
Secondary	OS	Overall survival rate	1 years